[Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
A randomized trial was done in 98 post-menopausal women with breast cancer. Hormonal receptors had not been assayed in any patient. Patients were given hormonal therapy with tamoxifen and drostanolone propionate (n = 34), or chemotherapy with the CMF protocol (n = 30), or a combination of both (n = 34). The results are in favour of hormonal therapy alone, which gave the best immediate objective responses, the least adverse side-effects, and possibly improved survival rates.
D000732:Androstanols / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008593:Menopause; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*
D000732:Androstanols; D011960:Receptors, Estrogen; D013629:Tamoxifen; C100263:dromostanolone; D003520:Cyclophosphamide; D005472:Fluorouracil; C007561:dromostanolone propionate; D008727:Methotrexate
Le traitement des cancers du sein dépassés chez la femme ménopausée. Etude comparative de l'hormonothérapie, de la chimiothérapie et de l'hormono-chimiothérapie.